Gilead Sciences Stock Rating Reaffirmed by TheStreet (GILD)
Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating reiterated by equities researchers at TheStreet in a research report issued on Tuesday, StockRatingsNetwork reports.
The analysts wrote, “Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.”
Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Gilead Sciences (NASDAQ:GILD) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, September 25th. They now have a $66.00 price target on the stock. Separately, analysts at Ameriprise Financial initiated coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note to investors on Thursday, September 19th. They set a “buy” rating on the stock. Six analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and an average target price of $67.57.
In other Gilead Sciences news, EVP Kevin Young sold 100,000 shares of the company’s stock on the open market in a transaction dated Monday, September 23rd. The stock was sold at an average price of $62.88, for a total transaction of $6,288,000.00. Following the transaction, the executive vice president now directly owns 161,840 shares in the company, valued at approximately $10,176,499. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 0.02% during mid-day trading on Tuesday, hitting $62.86. The stock had a trading volume of 1,662,577 shares. Gilead Sciences has a 52 week low of $32.07 and a 52 week high of $64.74. The stock’s 50-day moving average is $61.08 and its 200-day moving average is $55.19. The company has a market cap of $96.215 billion and a price-to-earnings ratio of 35.18.
Gilead Sciences (NASDAQ:GILD) last released its earnings data on Thursday, July 25th. The company reported $0.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.50. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the previous year, the company posted $0.99 earnings per share. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. Analysts expect that Gilead Sciences will post $1.97 EPS for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.